INS and COVID-19: Since the beginning of the pandemic, clinicians and researchers have been scared that SGLT-2 inhibitors, GLP-1 receptor agonists, pioglitazone, and insulin might lead to overexpression of ACE-2 receptor and thus cause more SARS-Cov-2 infections and worse COVID-19 outcomes.